Rapamycin enhances CAR-T control of HIV replication and reservoir elimination in vivo
Journal of Clinical Investigation · 2025
DOI: 10.1172/jci185489 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Wenli Mu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Department of Medicine, and. Hauptthemen laut MEDLINE: Sirolimus, Virus Replication, HIV Infections, HIV-1. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDA NIH HHS, NCI NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
Chimeric antigen receptor (CAR) T cell therapy shows promise for various diseases. Our studies in humanized mice and nonhuman primates demonstrate that hematopoietic stem cells (HSCs) modified with anti-HIV CAR achieve lifelong engraftment, providing functional antiviral CAR-T cells that reduce viral rebound after antiretroviral therapy (ART) withdrawal. However, T cell exhaustion due to chronic immune activation remains a key obstacle to sustained CAR-T efficacy, necessitating additional measures to achieve functional cure. We recently showed that low-dose rapamycin treatment reduced inflammation and improved anti-HIV T cell function in HIV-infected humanized mice. Here, we report that rapamycin improved CAR-T cell function both in vitro and in vivo. In vitro treatment with rapamycin enhanced CAR-T cell mitochondrial respiration and cytotoxicity. In vivo treatment with low-dose rapamycin in HIV-infected, CAR-HSC mice decreased chronic inflammation, prevented exhaustion of CAR-T cells, and improved CAR-T control of viral replication. RNA-sequencing analysis of CAR-T cells from humanized mice showed that rapamycin downregulated multiple checkpoint inhibitors and upregulated key survival genes. Mice treated with CAR-HSCs and rapamycin had delayed viral rebound after ART and reduced HIV reservoir compared with those treated with CAR-HSCs alone. These findings suggest that HSC-based anti-HIV CAR-T cells combined with rapamycin treatment are a promising approach for treating persistent inflammation and improving immune control of HIV replication.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology/Oncology, Department of Medicine, and.
- UCLA AIDS Institute and the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
- Department of Microbiology & Molecular Genetics and.
- Division of Infectious Diseases, Department of Medicine, School of Medicine, University of California, Irvine, Irvine, California, USA.
Förderung
- NIDA NIH HHS
- NCI NIH HHS
- NIAID NIH HHS
- NIAID
- NIDA
- American Foundation for AIDS Research
- NCI
- NIH
Zitieren
APA
Mu, W., Tomer, S., Harding, J., Kedia, N., Rezek, V., Cook, E., Patankar, V., Carrillo, M. A., Martin, H., Ng, H., Wang, L., Marsden, M. D., Kitchen, S. G., & Zhen, A. (2025). Rapamycin enhances CAR-T control of HIV replication and reservoir elimination in vivo. Journal of Clinical Investigation. https://doi.org/10.1172/jci185489
Vancouver
Mu W, Tomer S, Harding J, Kedia N, Rezek V, Cook E, et al. Rapamycin enhances CAR-T control of HIV replication and reservoir elimination in vivo. Journal of Clinical Investigation. 2025. doi:10.1172/jci185489
BibTeX
@article{Mu2025,
author = {Mu, Wenli and Tomer, Shallu and Harding, Jeffrey and Kedia, Nandita and Rezek, Valerie and Cook, Ethan and Patankar, Vaibahavi and Carrillo, Mayra A and Martin, Heather and Ng, Hwee and Wang, Li and Marsden, Matthew D and Kitchen, Scott G and Zhen, Anjie},
title = {Rapamycin enhances CAR-T control of HIV replication and reservoir elimination in vivo},
journal = {Journal of Clinical Investigation},
year = {2025},
doi = {10.1172/jci185489}
}
EUVIMED